explore -WSS

explore

author：focus 2025-09-07 17:27:45 - browse：79

Illustration: Alex Hogan/STAT; Photo: Courtesy Perrigo

It’s not every day that a marketing team is tasked with designing the branding and packaging of the first over-the-counter birth control pill to be sold in the U.S.

This was the challenge, and the opportunity, faced by the team behind Opill, the landmark pill from drugmaker Perrigo that received approval from the Food and Drug Administration earlier this month. Their brief: Create a design that would stand out in America’s notoriously sprawling pharmacy aisles; inspire trust and confidence; be easy to remember and recognize; appeal to women — including teenagers — as well as trans men and nonbinary people; clearly communicate its purpose; be simple to carry and use; contain straightforward but accurate user information; and clear FDA requirements.

Settling on the right approach took years of research and testing, which resulted in the name Opill and packaging featuring bright teal, saturated pink, and yellow, as well as a rounded font reminiscent of millennials’ ubiquitous favorite Gotham. All of these features are intended to set the product apart from the dozens of prescription contraceptive pills available in the U.S. market and internationally.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Apple Watch's A

Wikipedia

WSS

ASCO: Palliative care found as helpful given virtually as in person

Researchers on aging grapple with how to calculate biological age

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Dairy farmers resist CDC push for PPE against bird flu virus

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Kaiser's Risant Health gobbled up Geisinger. Who is next?

explore

explore

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

United colonoscopy coverage change 'may cost lives,' doctors say

Intellia reports positive results for its CRISPR

BioMarin wins approval for gene therapy to treat hemophilia A

Intellia reports positive results for its CRISPR

In age of alternative facts, a scholarly course on calling out crap

Google says AlphaFold 3 can map a vast universe of biomolecules

Medicare details structure of new drug price negotiation program

Elevance, private equity launch primary care company

focus

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Ultragenyx gene therapy for rare liver ailment succeeds in late

Medicare says breakthrough device reimbursement rule to come by summer

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

knowledge

Wikipedia

explore